Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.
Abstract
INTRODUCTION: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the human population affecting an estimated 8% of the world population, especially those living in areas of past and present malaria endemicity. Decreased G6PD enzymatic activity is associated with drug-induced hemolysis and increased risk of severe neonatal hyperbilirubinemia leading to brain damage. The G6PD gene is on the X chromosome therefore mutations cause enzymatic deficiency in hemizygote males and homozygote females while the majority of heterozygous females have an intermediate activity (between 30-80% of normal) with a large distribution into the range of deficiency and normality. Current G6PD qualitative tests are unable to diagnose G6PD intermediate activities which could hinder wide use of 8-aminoquinolines for Plasmodium vivax elimination. The aim of the study was to assess the diagnostic performances of the new Carestart G6PD quantitative biosensor. METHODS: A total of 150 samples of venous blood with G6PD deficient, intermediate and normal phenotypes were collected among healthy volunteers living along the north-western Thailand-Myanmar border. Samples were analyzed by complete blood count, by gold standard spectrophotometric assay using Trinity kits and by the latest model of Carestart G6PD biosensor which analyzes both G6PD and hemoglobin. RESULTS: Bland-Altman comparison of the CareStart normalized G6PD values to that of the gold standard assay showed a strong bias in values resulting in poor area under-the-curve values for both 30% and 80% thresholds. Performing a receiver operator curve identified threshold values for the CareStart product equivalent to the 30% and 80% gold standard values with good sensitivity and specificity values, 100% and 92% (for 30% G6PD activity) and 92% and 94% (for 80% activity) respectively. CONCLUSION: The Carestart G6PD biosensor represents a significant improvement for quantitative diagnosis of G6PD deficiency over previous versions. Further improvements and validation studies are required to assess its utility for informing radical cure decisions in malaria endemic settings.
Overview
CoChat Summary
TL;DR
The CareStart quantitative G6PD biosensor was validated against gold-standard spectrophotometry in 150 venous blood samples from the Thai-Myanmar border. It showed poor AUC when equivalent 30% and 80% thresholds were assumed, but optimized thresholds gave good sensitivity and specificity, supporting improvement over qualitative tests while requiring further field validation.
Key findings
- Bland-Altman comparison showed a strong bias, with the CareStart biosensor overestimating G6PD activity at low activity; AUC was 0.52 (95% CI 0.49–0.55) at the 30% threshold and 0.91 (95% CI 0.86–0.96) at the 80% threshold when equivalent thresholds were assumed.
- Using Youden’s Index, the optimal CareStart threshold for detecting gold-standard activity <30% (2.37 IU/gHb) was 4.55 IU/gHb, with 100% sensitivity and 92% specificity; for <80% (6.33 IU/gHb), the optimal threshold was 6.10 IU/gHb, with 92% sensitivity and 94% specificity.
- Replicate correlation was R² = 0.83 for G6PD activity and R² = 0.94 for Hb; biosensor Hb agreed with CBC Hb at R² = 0.88. Median activity in normal males was 7.91 IU/gHb by spectrophotometry and 7.85 IU/gHb by CareStart.
- For females only, at the 6.10 IU/gHb threshold for 80% activity, sensitivity and specificity were reported as 90% and 92.5%, respectively.
Methods
- Targeted convenience sample of 150 healthy volunteers aged >18 years along the north-western Thailand-Myanmar border: 42 males and 108 females, aiming for approximately 50 G6PD-deficient, 50 heterozygous female, and 50 G6PD-normal volunteers.
- Venous blood was collected in K2 EDTA; CBC was performed within 8 hours, and the Trinity spectrophotometric G6PD assay and CareStart biosensor were performed the following day within 30 hours. Each sample was run in duplicate on the biosensor, which measured both Hb and G6PD activity and reported G6PD as U/gHb.
- Analysis included linear regression for replicate correlation, Bland-Altman comparison against the reference assay, ROC AUC at different activity thresholds, and Youden’s Index to identify optimal CareStart thresholds; analyses used Stata 13.0.
Limitations
- Stated by the authors: the study was performed in a laboratory setting with regulated temperature and humidity, so testing under multiple environmental conditions reflective of hot tropical climates is needed; specific validation is needed for newborns using cord blood; no cost analysis was performed because prices were unavailable at submission.
- Stated by the authors: the ideal thresholds for discriminating activities between 30% and 80% normal were “alarmingly narrow,” with a range of only 1.55 IU/gHb (4.55–6.10).
- Evident from the text: the targeted convenience sample was not population-based, and the study assessed diagnostic performance rather than clinical outcomes; the device required at least 14 μL total blood, and volumes below 5 μL gave incorrect results without an alarm.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 26 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CareStart biosensor performed poorly in detecting deficient subjects at the 30% spectrophotometric activity threshold (<2.37IU/gHb) with an AUC of 0.52.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Results > Clinical performances of the CareStart G6PD biosensor
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nevertheless, using a higher activity threshold (in this case 4.55IU/gHb) maximized the sensitivity and specificity of the test for diagnosis of deficient samples with <30% activity by spectrophotometry.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the female population only, where discrimination of intermediate and normal activities is paramount for correct deployment of primaquine and especially tafenoquine, the sensitivity and specificity were acceptable (90% and 92.5% respectively) when a threshold of 6.10IU/gHb for 80% activity was used.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
None of the sources cited for this claim have been checked yet.
In the paper
“testing for G6PD deficiency on umbilical cord blood or very early in the neonatal period using qualitative rapid tests has been shown to be unreliable [23] because of reticulocytosis [24].”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Introduction
What the sources say
- Not checked yetcites [23] L Thielemans, 2018, Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study, Wellcome open research source
- Not checked yetcites [24] GS Paterakis, 1993, Flow-cytometric analysis of reticulocytes in normal cord blood, Acta haematologica source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, quantitative G6PD tests in these populations can play a role in diagnosing G6PD deficiency more accurately in neonates.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Introduction
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
3 more claims
Create a free account to see all 37 claims and to verify the 19 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Samples having hemoglobin measurements of less than 10 g/dL were excluded from further analyses in order to avoid the impact of anemia causing falsely elevated G6PD readings [22].”
In the citing paper
“Qualitative screening cannot reliably differentiate G6PD normal patients from those having >30% to <80% of normal enzyme activity [21,22].”
Citations
Cites
Glucose-6-phosphate dehydrogenase deficiency
Cappellini, M., & Fiorelli, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60073-2 · Cited by 1,590
Receiver operating characteristic (ROC) curve for medical researchers
Kumar, R., & Indrayan, A. (2011) · Indian Pediatrics · doi:10.1007/s13312-011-0055-4 · Cited by 872
Howes, R. E., Piel, F. B., Patil, A. P., Nyangiri, O. A., Gething, P. W., Dewi, M., Hogg, M. M., Battle, K. E., Padilla, C. D., Baird, J. K., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001339 · Cited by 562
Beutler, E., Blume, K. G., Kaplan, J. C., Löhr, G. W., Ramot, B., & Valentine, W. N. (1977) · British Journal of Haematology · doi:10.1111/j.1365-2141.1977.tb00589.x · Cited by 533
Glucose-6-Phosphate Dehydrogenase Deficiency
Luzzatto, L., Nannelli, C., & Notaro, R. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.11.006 · Cited by 400
Medications and Glucose-6-Phosphate Dehydrogenase Deficiency: An Evidence-Based Review
Youngster, I., Arcavi, L., Schechmaster, R., Akayzen, Y., Popliski, H., Shimonov, J., Beig, S., & Berkovitch, M. (2010) · Drug Safety · doi:10.2165/11536520-000000000-00000 · Cited by 258
Domingo, G. J., Satyagraha, A. W., Anvikar, A., Baird, K., Bancone, G., Bansil, P., Carter, N., Cheng, Q., Culpepper, J., Eziefula, C., et al. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-391 · Cited by 160
Self-citationChu, C. S., Bancone, G., Moore, K. A., Win, H. H., Thitipanawan, N., Po, C., Chowwiwat, N., Raksapraidee, R., Wilairisak, P., Phyo, A. P., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002224 · Cited by 146
Self-citationManagement of relapsing Plasmodium vivax malaria
Chu, C. S., & White, N. J. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1220304 · Cited by 130
Self-citationBetuela, I., Rosanas-Urgell, A., Kiniboro, B., Stanisic, D. I., Samol, L., de Lazzari, E., del Portillo, H. A., Siba, P., Alonso, P. L., Bassat, Q., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis580 · Cited by 118
Cited by
Lee, H. Y., Ithnin, A., Sabudin, R. Z. A. R., Othman, A., Salvador, A., & Cheah, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.875877 · Cited by 159
The prevention and treatment of Plasmodium vivax malaria
Chu, C. S., & White, N. J. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003561 · Cited by 88
Self-citationPal, S., Bansil, P., Bancone, G., Hrutkay, S., Kahn, M., Gornsawun, G., Penpitchaporn, P., Chu, C. S., Nosten, F., & Domingo, G. J. (2018) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.18-0612 · Cited by 91
Self-citationLaboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline
Roper, D. R., Layton, M. D., Rees, D. C., Lambert, C., Vulliamy, T., la Salle, B. D., D’Souza, C., & the British Society for Haematology (2020) · British Journal of Haematology · doi:10.1111/bjh.16366 · Cited by 72
Bancone, G., Menard, D., Khim, N., Kim, S., Canier, L., Nguong, C., Phommasone, K., Mayxay, M., Dittrich, S., Vongsouvath, M., et al. (2019) · Malaria Journal · doi:10.1186/s12936-019-2652-y · Cited by 50
Self-citation
Metadata
- Authors
- Bancone, G., Gornsawun, G., Chu, C. S., Porn, P., Pal, S., Bansil, P., Domingo, G. J., & Nosten, F.
- Affiliations
- Mahidol University (TH)
- Program for Appropriate Technology in Health (US)
- Corresponding author
- Bancone, Germana
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-05-08
- Volume
- 13
- Issue
- 5
- Pages
- e0196716
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5940185
- OpenAlex
- W2802195192
- Semantic Scholar
- 08256ddb3f46de91cb36b97964a2f9f551d89a13
- Cited by
- 65
- References
- 32
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 3
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Bill and Melinda Gates Foundation (OPP1034534)
- Department for International Development, UK Government (204139)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Keywords
- glucose-6-phosphate dehydrogenase deficiency, G6PD activity, point-of-care testing, quantitative diagnosis, diagnostic accuracy, Plasmodium vivax, 8-aminoquinolines, hemolysis, neonatal hyperbilirubinemia
- MeSH terms
- Adult, Aminoquinolines, Antimalarials, Myanmar, Clinical Enzyme Tests, Ethnicity, Female, Genotype, Glucosephosphate Dehydrogenase, Glucosephosphate Dehydrogenase Deficiency, Hemoglobinometry, Humans, Male, Methemoglobinemia, Pregnancy, Pregnancy Complications, Hematologic, Primaquine, ROC Curve, Spectrophotometry, Ultraviolet, Biosensing Techniques, Malaria, Vivax, Point-of-Care Systems, Endemic Diseases, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. https://app.cochat.ai/papers/10.1371/journal.pone.0196716
- The paper
- Bancone, G., Gornsawun, G., Chu, C. S., Porn, P., Pal, S., Bansil, P., Domingo, G. J., & Nosten, F. (2018). Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PLOS ONE. https://doi.org/10.1371/journal.pone.0196716
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.